Imvotamab by IGM Biosciences for Rheumatoid Arthritis: Likelihood of Approval

Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Rheumatoid Arthritis.

Related Posts

STAT+: Medicare eyes cuts to doctors, raises to outpati...

Jul 14, 2023

Rollout of a new malaria vaccine kicks off in Africa

Jan 22, 2024

FDA accepts BeiGene’s sNDA for follicular lymphoma therapy

Jul 13, 2023